SCHEMBL7185628

SCHEMBL7185628

Cc1cccc(Cl)c1C(=O)C(c1ccccc1)C(C)(C)CC(C)CP=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM4 Q8TD43 1/20 0.36
FABP3 P05413 1/20 0.34
FABP4 P15090 1/20 0.34
KCNQ2 O43526 1/20 0.34
UTS2R Q9UKP6 1/20 0.33
CCR5 P51681 1/20 0.33
ITGB1 P05556 3/20 0.32
ITGA4 P13612 3/20 0.32
ITGB2 P05107 1/20 0.32
ICAM1 P05362 1/20 0.32
ITGAL P20701 1/20 0.32
ITGA2 P17301 1/20 0.32
ITGB7 P26010 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
PTGS2 P35354 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CYP2C9 P11712 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189082 0.93 KCNQ2 (0.36) KCNQ2ITGB1ITGA4MEN1POLB
SCHEMBL7180620 0.86 FABP4 (0.38) FABP4ITGB1ITGA4MEN1POLB
SCHEMBL7183832 0.83 LMNA (0.34) MEN1KMT2AL3MBTL1
SCHEMBL7183943 0.82 CYP1A2 (0.33) MEN1KMT2AL3MBTL1CYP2C9
SCHEMBL7183707 0.81 ATM (0.30) L3MBTL1
SCHEMBL7183923 0.80 ATM (0.34) FABP4MEN1POLBKMT2AL3MBTL1
SCHEMBL7187536 0.80 CA12 (0.38) MEN1POLBKMT2AL3MBTL1
SCHEMBL7181376 0.79 FABP3 (0.40) TRPM4FABP3FABP4KCNQ2UTS2R
SCHEMBL610991 0.78 ALDH1A1 (0.34) MEN1POLBKMT2ARAB9ATYK2
SCHEMBL7182855 0.78 KCNQ2 (0.43) TRPM4FABP3FABP4KCNQ2UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TRPM4 3654/4885FABP3 3252/4885FABP4 4550/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TRPM4 3840/4885FABP3 2807/4885FABP4 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.